

IMPACT OF PHARMACEUTICAL PROPOSALS IN MULTIDISCIPLINARY PROGRAMME FOR CLINICAL DECISION-MAKING IN IMMUNE-MEDIATED INFLAMMATORY DISEASES

M.D. GIL-SIERRA¹, M.D.P. BRICEÑO CASADO², C. MORENO-RAMOS¹, M.A. BLANCO-CASTAÑO¹, C.M. CUADROS-MARTINEZ³.

¹HOSPITAL UNIVERSITARIO DE PUERTO REAL, PHARMACY, PUERTO REAL, SPAIN.

²HOSPITAL UNIVERSITARIO DE JEREZ DE LA FRONTERA, HOSPITAL PHARMACY, JEREZ DE LA FRONTERA CÁDIZ, SPAIN.

³HOSPITAL UNIVERSITARIO DE JEREZ DE LA FRONTERA, PHARMACY, JEREZ DE LA FRONTERA, SPAIN.

Section 4: Clinical Pharmacy Services

4CPS-030

BACKGROUND

Pharmaceutical proposals (PPs) in a **multidisciplinary programme (MP)** for immune-mediated inflammatory diseases could improve drug **effectiveness** and **efficiency** of clinical decision-making.

AIM

To evaluate the **impact of PPs in a MP** for the management of **immune-mediated inflammatory dermatological and rheumatological diseases**.

MATERIAL AND METHODS

MP during **May 2021-September 2022**


Patients



Patients with **rheumatoid arthritis (RA), spondyloarthritis, psoriasis and psoriatic arthritis (PA)** receiving etanercept or adalimumab for at least 6 months

Multidisciplinary programme (MP): internists, dermatologists, pharmacologists and pharmacists

- Bibliographic search on **optimal therapeutic ranges (OTRs)** of drugs
- PP protocol based on **biochemical** and **clinical criteria**.
- **Pharmaceutical interviews (PIs)** about disease evolution were conducted before PPs.



PPs were:

- **Treatment optimisation (TO)** based on extended dosing regimens or treatment discontinuations.
- **Drug switching (DS)** due to loss of effectiveness
- **Unchanged therapy (UT)**

Patients with accepted TO had **telematic PIs** after 1 and 3 months (answers: "good course"/"mild disease"/"poor course")

Recorded data: drugs, multidisciplinary meetings, biochemical test and PIs, drugs levels and anti-drug antibodies, type of accepted PPs and telematic PI answers.

RESULTS

- **Total Patients:** 645
- **Drug distribution:** 51.8% etanercept and 48.2% adalimumab
- **Multidisciplinary meetings:** 25
- **Biochemical test and pharmaceutical interviews:** 408
- **Results of bibliographic search:**
 - Adalimumab: OTRs of 5-8 µg/mL for RA and PA, 3.2-7 µg/mL for psoriasis and 4.6-12 µg/mL for spondyloarthritis.
 - Etanercept OTRs: 2-3 µg/mL for RA and spondyloarthritis, and 2-7 µg/mL for PA and psoriasis.
- **Serum drug levels:** outside the optimal therapeutic ranges in 72.9%
- **Anti-drug antibodies:** 18 patients.

Pharmaceutical proposals

PPs accepted: 305

Distribution:

- **Treatment optimisation:** 183 (60%)
- **Drug switching:** 52 (17%)
- **Unchanged therapy:** 70 (23%)

Telematic PIs answers:

- **At 1 month after TO were:** 81.8% "good course", 3.6% "mild disease" and 14.6% "poor course"
- **At 3 months were:** 69.8% "good course", 5.7% "mild disease" and 24.5% "poor course".

CONCLUSION

Most of **accepted PPs** in our MP (DS and TO) can **improve effectiveness** and **efficiency of treatments** for immune-mediated inflammatory diseases in clinical decision-making. Almost **three quarters of patients** with TO presented **good disease evolution**.

CONTACT DATA

E-mail: mangilsie@yahoo.com

